PV Bulletin

Mandatory Submission of Briefing Documents for Scientific Advice Requests

The MHRA has established a new requirement for organisations to submit full briefing documents at the point of submitting a scientific advice request, effective from September 2026.

Primary source: Medicines: Get integrated scientific advice from the MHRA and NICE

PV Impact Brief

Urgency: HighConfidence: high

What changed

Starting in September 2026, it is mandatory for organizations to submit full briefing documents along with their scientific advice requests. This introduces an earlier checkpoint for preparing safety-related materials such as RMPs and PASS protocols.

Why it matters

This change necessitates that pharmacovigilance teams intensify their efforts to finalize safety documentation much earlier in the product development lifecycle, thereby increasing coordination between regulatory and pharmacovigilance teams.

Action needed

PV teams must prepare and finalize safety-related briefing materials, including risk management plans and protocols, for initial submission by September 2026.

Relevant for
Regulatory Intelligence LeadSignal Management LeadQPPV
Processes impacted
Country ComplianceSignal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review before 2026-09-01.

Policy change details

Document type
Guidance / Process Change
Policy status
revised
Publication date
2014-12-29
Last updated
2026-08-14
Coming into force
2026-09-01
Effective date
2026-08-14
Policy change
The MHRA updated its guidance on scientific advice to introduce a new procedural requirement for the submission of briefing materials. Starting in September 2026, organisations must provide full briefing documents at the point of submission of a scientific advice request, rather than later in the process.

Key changes

Mandatory submission of the full briefing document(s) at the point of request for scientific advice; implementation effective from September 2026.

Affected workflows

Country ComplianceSignal Management

Responsible groups

Regulatory AffairsPharmacovigilance OperationsClinical Safety

PV impact

This change requires PV teams to finalize safety-related briefing materials—including RMPs, PASS protocols, and risk management strategies—much earlier in the development lifecycle. Regulatory and PV coordination must be intensified to ensure all safety documentation is ready for the initial submission.

View regulator source

Source document details

Exact policy details

Submission of Briefing Document
Final briefing document(s) must be submitted at the point of request.
Applies to: Mandatory from September 2026 for all organizations requesting scientific advice.
Updated to inform organisations that they are required to submit their final briefing document(s) and questions at the point of requesting Scientific Advice, with this becoming mandatory from September 2026. · p. 1 · High · Source
Response Timeline
MHRA will provide meeting date or timeline for written advice within 10 working days of submission acknowledgment.
Applies to: All requests for scientific advice.
A contact person from the MHRA will offer a meeting date (or for written advice, provide a timeline of when the advice letter will be sent) within 10 working days of the acknowledgment of the submission, provided the request is in scope. · p. 1 · High · Source
Written Advice after Meeting
Final advice letter will be sent within 30 working days after the meeting.
Applies to: Applicable for scientific advice meetings.
If offered, the MHRA will send this final advice letter within 30 working days of the meeting taking place. · p. 1 · High · Source
Fee Payment Deadline
Fees must be paid at least 15 working days before the meeting.
Applies to: All requests for scientific advice that require a fee.
You need to pay at least 15 working days before your meeting date, or your meeting may be delayed. · p. 1 · High · Source
SME Fee Exemption
UK-based SMEs with approved status do not have to pay for scientific advice.
Applies to: UK-based SMEs with approved SME status.
UK-based small and medium-sized enterprises (SMEs) with approved SME status do not have to pay for scientific advice. · p. 1 · High · Source

Workflow rule impacts

ComplianceCompliance Officer

Increased preparation time and documentation requirements for organizations seeking advice.

Organizations must submit a briefing document at the point of submission.

From September 2026, organisations should provide the full briefing document(s) at the point of submission of a Scientific Advice request. · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Aug 14, 2026

Full briefing

Practical implication

PV teams must prepare and finalize safety-related briefing materials, including risk management plans and protocols, for initial submission by September 2026.

The MHRA has updated its procedural guidance on the submission of briefing materials for scientific advice requests. This change mandates that organizations must provide complete briefing documents at the time of submission, significantly earlier in the process than previously required.

What changed: Starting in September 2026, it is mandatory for organizations to submit full briefing documents along with their scientific advice requests. This introduces an earlier checkpoint for preparing safety-related materials such as RMPs and PASS protocols.

Why it matters: This change necessitates that pharmacovigilance teams intensify their efforts to finalize safety documentation much earlier in the product development lifecycle, thereby increasing coordination between regulatory and pharmacovigilance teams.

Practical implication: PV teams must prepare and finalize safety-related briefing materials, including risk management plans and protocols, for initial submission by September 2026.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward